← brief for 2026-10-14 · Slowing decline

Oral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification.

Paper No results yet Peer reviewed

Key takeaways

This review looks at oral weight-loss drugs. It argues these drugs should be judged by how well they protect the heart and kidneys, not just by weight loss. The article summarizes current options and their benefits. There are no new trial results in this piece.

Who did this work

Alhazmi A · Le Roux CW

Source

Paper · PubMed, the drug frontier · 2026 Oct 9
https://pubmed.ncbi.nlm.nih.gov/42871841/